

NeuroTherm[®]

FOR IMMEDIATE RELEASE

For More Information, please contact:
Toni Fournier, V.P. Marketing
(978 436 4336)/tfournier@neurotherm.com

NeuroTherm Acquires Assets from Technomed Europe

Wilmington, Massachusetts – February 8, 2010

NeuroTherm[®] announced today that they have acquired the Interventional Pain assets from Technomed Europe. Based in the Netherlands, Technomed Europe is a developer, manufacturer and supplier of neuro-diagnostic accessories, including specialty needles used in the practice of Interventional Pain Medicine. Under the terms of the acquisition, NeuroTherm acquired all intellectual property and manufacturing know-how associated with this product line.

“NeuroTherm’s management team has been focused on reducing costs, improving margin and controlling more aspects of the supply chain for some time. The Technomed deal represents another significant step towards achieving these goals,” according to Jeffrey A. Lipsitz, a Partner at Cortec. NeuroTherm is a portfolio company of Cortec Group Fund III, L.P. (“Cortec Fund III”).

The acquisition of Technomed Assets represents the third add-on acquisition for NeuroTherm since the company was incorporated in 2005.

NeuroTherm is a leading manufacturer of products used in the field of Interventional Pain, including radio frequency generators and related consumables used in the treatment of chronic pain. The company was awarded a US Patent #7,574,257 in recognition of the first multi-lesion radiofrequency generator on the market. NeuroTherm markets and sells to Interventional Pain, Interventional Radiology, Orthopedic and Foot & Ankle Specialists. Foot & Ankle Physicians and Podiatrists use radiofrequency to treat pain associated with Plantar Fasciitis & Neuroma.

NeuroTherm is based in Wilmington, Massachusetts with corporate offices in London, UK and Amsterdam, NL. Additional information about NeuroTherm can be found on at www.neurotherm.com.

###
